eFFECTOR Therapeutics announced a collaboration to conduct an investigator-sponsored trial evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive endometrial cancer and low grade serous ovarian cancer at the Dana-Farber Cancer Institute under the direction of Panagiotis Konstantinopoulos, M.D., Ph.D., Director of Translational Research and attending oncologist in the Division of Gynecologic Oncology at DFCI, and an Associate Professor of Medicine at Harvard Medical School.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EFTR:
- eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16)
- eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
- eFFECTOR Therapeutics trading resumes
- eFfector sees no ‘obvious’ path forward for tomivosertib development in NSCLC